Rocket Pharmaceuticals Inc
RCKT2.510USD
-0.110-4.20%
Close 05/30, 16:00（ET）Quotes delayed by 15 min
267.95MMarket Cap
LossP/E TTM
More Details of Rocket Pharmaceuticals Inc Company
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
Company Info
Company codeRCKT
Company nameRocket Pharmaceuticals Inc
IPO dateFeb 18, 2015
Founded at1999
CEODr. Gaurav D. Shah, M.D.
Number of employees299
Security typeOrdinary Share
Fiscal year-endFeb 18
Address9 Cedarbrook Drive
CityCRANBURY
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code08512
Phone16464409100
Websitehttps://www.rocketpharma.com/
Company codeRCKT
IPO dateFeb 18, 2015
Founded at1999
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Gaurav D. Shah, M.D.
Dr. Gaurav D. Shah, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.21M
-0.48%
Dr. Gotham Makker, M.D.
Dr. Gotham Makker, M.D.
Independent Director
Independent Director
621.50K
-24.19%
Dr. Kinnari Patel, Pharm.D.
Dr. Kinnari Patel, Pharm.D.
President, Chief Operating Officer, Head of Research and Development
President, Chief Operating Officer, Head of Research and Development
513.63K
-0.42%
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
95.12K
-0.04%
Mr. John Militello, CPA
Mr. John Militello, CPA
Principal Accounting Officer, Vice President - Finance, Treasurer
Principal Accounting Officer, Vice President - Finance, Treasurer
57.84K
-1.72%
Mr. Aaron Ondrey
Mr. Aaron Ondrey
Chief Financial Officer, Principal Financial Officer
Chief Financial Officer, Principal Financial Officer
19.52K
-85.77%
Dr. Mikael G. Dolsten, M.D., Ph.D.
Dr. Mikael G. Dolsten, M.D., Ph.D.
Independent Director
Independent Director
14.22K
--
Mr. Pedro Granadillo
Mr. Pedro Granadillo
Independent Director
Independent Director
--
--
Ms. Sarbani Chaudhuri
Ms. Sarbani Chaudhuri
Chief Commercial and Medical Affairs Officer
Chief Commercial and Medical Affairs Officer
--
--
Dr. Jonathan Schwartz, M.D.
Dr. Jonathan Schwartz, M.D.
Chief Medical and Gene Therapy Officer
Chief Medical and Gene Therapy Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Gaurav D. Shah, M.D.
Dr. Gaurav D. Shah, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.21M
-0.48%
Dr. Gotham Makker, M.D.
Dr. Gotham Makker, M.D.
Independent Director
Independent Director
621.50K
-24.19%
Dr. Kinnari Patel, Pharm.D.
Dr. Kinnari Patel, Pharm.D.
President, Chief Operating Officer, Head of Research and Development
President, Chief Operating Officer, Head of Research and Development
513.63K
-0.42%
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
95.12K
-0.04%
Mr. John Militello, CPA
Mr. John Militello, CPA
Principal Accounting Officer, Vice President - Finance, Treasurer
Principal Accounting Officer, Vice President - Finance, Treasurer
57.84K
-1.72%
Mr. Aaron Ondrey
Mr. Aaron Ondrey
Chief Financial Officer, Principal Financial Officer
Chief Financial Officer, Principal Financial Officer
19.52K
-85.77%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sat, May 17
Update time: Sat, May 17
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
RTW Investments L.P.
16.42%
Wellington Management Company, LLP
6.64%
The Vanguard Group, Inc.
6.13%
BlackRock Institutional Trust Company, N.A.
5.71%
Maverick Capital, Ltd.
5.15%
Other
59.96%
Shareholder Statistics
Shareholder
Proportion
RTW Investments L.P.
16.42%
Wellington Management Company, LLP
6.64%
The Vanguard Group, Inc.
6.13%
BlackRock Institutional Trust Company, N.A.
5.71%
Maverick Capital, Ltd.
5.15%
Other
59.96%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
51.25%
Investment Advisor
20.03%
Hedge Fund
18.39%
Research Firm
4.48%
Individual Investor
2.60%
Bank and Trust
1.28%
Venture Capital
1.25%
Private Equity
1.13%
Pension Fund
0.17%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
469
117.28M
110.07%
+11.74M
2024Q4
469
115.66M
108.78%
+9.90M
2024Q3
442
99.39M
108.64%
-6.54M
2024Q2
434
97.04M
106.63%
-8.16M
2024Q1
431
98.54M
108.92%
-3.20M
2023Q4
427
94.76M
105.15%
-7.91M
2023Q3
413
94.89M
105.90%
+6.62M
2023Q2
408
81.61M
101.38%
-10.66M
2023Q1
419
83.81M
105.83%
-4.94M
2022Q4
433
80.68M
102.32%
-522.65K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RTW Investments L.P.
17.69M
16.59%
--
--
Dec 31, 2024
Wellington Management Company, LLP
14.00M
13.13%
+2.75M
+24.49%
Dec 31, 2024
The Vanguard Group, Inc.
6.56M
6.16%
+1.04M
+18.84%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.63M
5.28%
+524.20K
+10.26%
Dec 31, 2024
Maverick Capital, Ltd.
5.20M
4.88%
+1.08M
+26.23%
Dec 31, 2024
Westfield Capital Management Company, L.P.
4.71M
4.42%
+220.78K
+4.91%
Dec 31, 2024
State Street Global Advisors (US)
3.46M
3.24%
+356.06K
+11.48%
Dec 31, 2024
Suvretta Capital Management, LLC
2.57M
2.41%
+2.57M
--
Dec 31, 2024
Janus Henderson Investors
4.00M
3.76%
+2.11M
+111.03%
Dec 31, 2024
T. Rowe Price Associates, Inc.
3.09M
2.9%
-34.49K
-1.10%
Dec 31, 2024
View more
Related ETFs
Update time: Tue, May 6
Update time: Tue, May 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.28%
Global X Genomics & Biotechnology ETF
1.18%
Harbor Health Care ETF
0.64%
Tema Cardiovascular and Metabolic ETF
0.35%
Main Thematic Innovation ETF
0.34%
SPDR S&P Biotech ETF
0.22%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
Federated Hermes MDT Small Cap Core ETF
0.12%
Franklin Genomic Advancements ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.07%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.28%
Global X Genomics & Biotechnology ETF
Proportion1.18%
Harbor Health Care ETF
Proportion0.64%
Tema Cardiovascular and Metabolic ETF
Proportion0.35%
Main Thematic Innovation ETF
Proportion0.34%
SPDR S&P Biotech ETF
Proportion0.22%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.14%
Federated Hermes MDT Small Cap Core ETF
Proportion0.12%
Franklin Genomic Advancements ETF
Proportion0.1%
ProShares Ultra Nasdaq Biotechnology
Proportion0.07%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
